Kangpu Biopharmaceuticals, Ltd. ('Kangpu') today announced that the Company has received IND approval from the CDE (Center ...

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Turnarounds are high stakes, high-pressure and unforgiving. Waste shouldn’t slow you down. When you’re up against tight ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Allogene Therapeutics is undervalued. Read more on ALLO stock's cash runway, innovative CAR-T therapies, and market expansion ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, 'CARsgen Therapeutics'), a company focused on innovative CAR ...